Subgroup analyses in reporting of phase III clinical trials in solid tumors

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1697-1702

  Zhang, Sheng ^a   Liang, Fei ^a   Li, Wenfeng ^b   Hu, Xichun ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL DECISION MAKING; COLORECTAL CANCER; ESOPHAGUS CANCER; HUMAN; LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; STOMACH CANCER; INFORMATION PROCESSING; METHODOLOGY; NEOPLASMS; ONCOLOGY; PROCEDURES; STATISTICAL ANALYSIS; STATISTICS; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 84933508215     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.8862     Document Type: Article

References (22)

1. Guyatt GH, Oxman AD, Vist GE, et al: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926, 2008
2. Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276:637-639, 1996
3. Moher D, Schulz KF, Altman DG: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-1194, 2001
4. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ 340:c332, 2010
5. Peron J, Pond GR, Gan HK, et al: Quality of reporting of modern randomized controlled trials in medical oncology: A systematic review. J Natl Cancer Inst 104:982-989, 2012
6. Kasenda B, Schandelmaier S, Sun X, et al: Subgroup analyses in randomised controlled trials: Cohort study on trial protocols and journal publications. BMJ 349:g4539, 2014
7. Sun X, Briel M, Busse JW, et al: The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: Systematic review. BMJ 342:d1569, 2011
8. Sun X, Briel M, Walter SD, et al: Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 340:c117, 2010
9. Sun X, Ioannidis JP, Agoritsas T, et al: How to use a subgroup analysis: Users' guide to the medical literature. JAMA 311:405-411, 2014
10. Peron J, Maillet D, Gan HK, et al: Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: A systematic review. J Clin Oncol 31:3957-3963, 2013
11. Sivendran S, Latif A, McBride RB, et al: Adverse event reporting in cancer clinical trial publications. J Clin Oncol 32:83-89, 2014
12. Sun X, Briel M, Busse JW, et al: Credibility of claims of subgroup effects in randomised controlled trials: Systematic review. BMJ 344:e1553, 2012
13. Dwan K, Altman DG, Clarke M, et al: Evidence for the selective reporting of analyses and discrepancies in clinical trials: A systematic review of cohort studies of clinical trials. PLoS Med 11:e1001666, 2014
14. Schulz KF, Grimes DA: Multiplicity in randomised trials II: Subgroup and interim analyses. Lancet 365:1657-1661, 2005
15. Rothwell PM: Treating individuals 2Su¯bgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet 365:176-186, 2005
16. Lagakos SW: The challenge of subgroup analyses: Reporting without distorting. N Engl J Med 354:1667-1669, 2006
17. Cuzick J: Forest plots and the interpretation of subgroups. Lancet 365:1308, 2005
18. Lazar AA, Cole BF, Bonetti M, et al: Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: Subpopulation treatment effect pattern plot. J Clin Oncol 28:4539-4544, 2010
19. Sydes MR, Langley RE: Potential pitfalls in the design and reporting of clinical trials. Lancet Oncol 11:694-700, 2010
20. Brookes ST, Whitely E, Egger M, et al: Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 57:229-236, 2004
21. Hernandez AV, Boersma E, Murray GD, et al: Subgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading? Am Heart J 151:257-264, 2006
22. Wang R, Lagakos SW, Ware JH, et al: Statistics in medicine: Reporting of subgroup analyses in clinical trials. N Engl J Med 357:2189-2194, 2007